LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article ; Online: Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.

2023 Volume 8, Issue 1, Page(s) 236–247

Abstract: Abstract: Multiple myeloma (MM) is twice as common in Black individuals compared with in White individuals, and diabetes mellitus (DM) disproportionately affects Black patients. Although numerous studies have shown a correlation between DM and MM, this ... ...

Abstract	Abstract: Multiple myeloma (MM) is twice as common in Black individuals compared with in White individuals, and diabetes mellitus (DM) disproportionately affects Black patients. Although numerous studies have shown a correlation between DM and MM, this has not been studied in the context of race and in vivo mechanisms. We conducted a retrospective clinical study of 5383 patients with MM of which 15% had DM (White, 12% and Black, 25%). Multivariable Cox models showed reduced overall survival (OS) for patients with DM (hazard ratio, 1.27; 95% confidence interval, 1.11-1.47; P < .001). This appeared to be driven by a marked difference in OS between White patients with and without DM but not in Black patients. In contrast, obesity was associated with better OS in Black patients but not in White patients. To complement this analysis, we assessed MM growth in a genetically engineered immunocompromised nonobese diabetic (Rag1-/-/muscle creatinine kinase promoter expression of a human IGF1R [M] with a lysine [K] to arginine [R] point mutation) mouse model to evaluate the mechanisms linking DM and MM. MM.1S xenografts grew in more Rag1-/-/MKR mice and grew more rapidly in the Rag1-/-/MKR mice compared with in controls. Western blot analysis found that MM1.S xenografts from Rag1-/-/MKR mice had higher phosphorylated S6 ribosomal protein (Ser235/236) levels, indicating greater activation of the mammalian target of rapamycin pathway. Our study is, to our knowledge, the first to evaluate racial differences in DM prevalence and survival in MM, as well as the effect of DM on tumor growth in mouse models. Our results suggest that DM may contribute to the higher incidence of MM in Black patients; and to improve survival in MM, DM management cannot be ignored.
MeSH term(s)	Animals ; Humans ; Mice ; Diabetes Mellitus ; Homeodomain Proteins ; Multiple Myeloma/epidemiology ; Prevalence ; Racial Groups ; Retrospective Studies ; White People ; Black People ; Survival Rate
Chemical Substances	Homeodomain Proteins
Language	English
Publishing date	2023-09-28
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023010815
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nutrition perceptions, needs and practices among patients with plasma cell disorders.

Blood cancer journal

2022 Volume 12, Issue 4, Page(s) 70

MeSH term(s)	Humans ; Nutritional Status ; Plasma Cells
Language	English
Publishing date	2022-04-20
Publishing country	United States
Document type	Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-022-00666-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.

Firestone, Ross S / McAvoy, Devin / Shekarkhand, Tala / Serrano, Edith / Hamadeh, Issam / Wang, Alice / Zhu, Menglei / Qin, Wei Ge / Patel, Dhwani / Tan, Carlyn R / Hultcrantz, Malin / Mailankody, Sham / Hassoun, Hani / Shah, Urvi S / Korde, Neha / Maclachlan, Kylee H / Landau, Heather J / Scordo, Michael / Shah, Gunjan L /

Lahoud, Oscar B / Giralt, Sergio / Murata, Kazunori / Hosszu, Kinga K / Chung, David J / Lesokhin, Alexander M / Usmani, Saad Z

Blood advances

2023 Volume 8, Issue 7, Page(s) 1600–1611

Abstract: Abstract: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and ... ...

Abstract	Abstract: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.
MeSH term(s)	Humans ; Multiple Myeloma/drug therapy ; B-Cell Maturation Antigen/therapeutic use ; Retrospective Studies ; Antineoplastic Agents/therapeutic use ; CD8-Positive T-Lymphocytes/metabolism
Chemical Substances	B-Cell Maturation Antigen ; Antineoplastic Agents
Language	English
Publishing date	2023-10-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023011225
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Barta, Stefan K / Zain, Jasmine / MacFarlane, Alexander W / Smith, Sonali M / Ruan, Jia / Fung, Henry C / Tan, Carlyn R / Yang, Yibin / Alpaugh, R Katherine / Dulaimi, Essel / Ross, Eric A / Campbell, Kerry S / Khan, Nadia / Siddharta, Rawat / Fowler, Nathan H / Fisher, Richard I / Oki, Yasuhiro

Clinical lymphoma, myeloma & leukemia

2019 Volume 19, Issue 6, Page(s) 356–364.e3

Abstract: Background: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of immune checkpoint inhibitors in the management of T-cell lymphomas.: Patients ... ...

Abstract	Background: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of immune checkpoint inhibitors in the management of T-cell lymphomas. Patients and methods: In this phase II single-arm multicenter trial, patients with relapsed or refractory systemic T-cell lymphoma were treated with 200 mg pembrolizumab intravenously every 21 days. The primary endpoint was progression-free survival (PFS). The secondary endpoints were response rate, overall survival, response duration, and safety. We assessed PD-L1, p-AKT expression, and peripheral blood immune cells as potential predictive biomarkers. Results: Of 18 enrolled patients, 13 were evaluable for the primary endpoint. The trial was halted early after a preplanned interim futility analysis. The overall response rate was 33% (95% confidence interval [CI], 9%-55%); 4 patients achieved a complete response (27%; 95% CI, 5%-49%). The median PFS was 3.2 months (95% CI, 1.2-3.7 months), and the median overall survival was 10.6 months (95% CI, 3.2-100 months). The median duration of response was 2.9 months (95% CI, 0-10.1 months). Two of the 4 complete responders remain in remission > 15 months. Rash was the most common adverse event (17%; n = 3). The most common ≥ grade 3 treatment-emergent adverse events were rash and pneumonitis (11%; n = 2 each). Neither PD-L1 nor p-AKT expression were associated with outcomes. However, a higher relative frequency of CD4 Conclusion: Pembrolizumab demonstrated modest single-agent activity in relapsed or refractory T-cell lymphoma.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Drug Resistance, Neoplasm ; Female ; Humans ; Kaplan-Meier Estimate ; Lymphoma, T-Cell, Peripheral/diagnosis ; Lymphoma, T-Cell, Peripheral/etiology ; Lymphoma, T-Cell, Peripheral/metabolism ; Lymphoma, T-Cell, Peripheral/therapy ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Recurrence ; Treatment Outcome ; Young Adult
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; Programmed Cell Death 1 Receptor ; pembrolizumab (DPT0O3T46P) ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1)
Language	English
Publishing date	2019-04-03
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2019.03.022
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

Tan, Carlyn R / Yaffee, Patrick M / Jamil, Laith H / Lo, Simon K / Nissen, Nicholas / Pandol, Stephen J / Tuli, Richard / Hendifar, Andrew E

Frontiers in physiology

2014 Volume 5, Page(s) 88

Abstract: Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge. Pancreatic cancer cachexia is a multifactorial syndrome ... ...

Abstract	Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge. Pancreatic cancer cachexia is a multifactorial syndrome characterized by uncompensated adipose tissue and skeletal muscle loss in the setting of anorexia that leads to progressive functional impairment. This paper will review the current concepts of pancreatic cancer cachexia, its assessment and pathophysiology as well as current and future treatments. The successful management of pancreatic cancer cachexia will likely require a multimodal approach that includes nutritional support and combination pharmaceutical interventions.
Language	English
Publishing date	2014-03-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2564217-0
ISSN	1664-042X
ISSN	1664-042X
DOI	10.3389/fphys.2014.00088
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: GPRC5D-Targeted CAR T Cells for Myeloma.

Mailankody, Sham / Devlin, Sean M / Landa, Jonathan / Nath, Karthik / Diamonte, Claudia / Carstens, Elizabeth J / Russo, Douglas / Auclair, Romany / Fitzgerald, Lisa / Cadzin, Briana / Wang, Xiuyan / Sikder, Devanjan / Senechal, Brigitte / Bermudez, Vladimir P / Purdon, Terence J / Hosszu, Kinga / McAvoy, Devin P / Farzana, Tasmin / Mead, Elena /

Wilcox, Jessica A / Santomasso, Bianca D / Shah, Gunjan L / Shah, Urvi A / Korde, Neha / Lesokhin, Alexander / Tan, Carlyn R / Hultcrantz, Malin / Hassoun, Hani / Roshal, Mikhail / Sen, Filiz / Dogan, Ahmet / Landgren, Ola / Giralt, Sergio A / Park, Jae H / Usmani, Saad Z / Rivière, Isabelle / Brentjens, Renier J / Smith, Eric L

The New England journal of medicine

2022 Volume 387, Issue 13, Page(s) 1196–1206

Abstract: Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) ... ...

Abstract	Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic target in multiple myeloma. Preclinical studies have shown the efficacy of GPRC5D-targeted CAR T cells, including activity in a BCMA antigen escape model. Methods: In this phase 1 dose-escalation study, we administered a GPRC5D-targeted CAR T-cell therapy (MCARH109) at four dose levels to patients with heavily pretreated multiple myeloma, including patients with relapse after BCMA CAR T-cell therapy. Results: A total of 17 patients were enrolled and received MCARH109 therapy. The maximum tolerated dose was identified at 150×10 Conclusions: The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).
MeSH term(s)	B-Cell Maturation Antigen/therapeutic use ; Cytokine Release Syndrome/etiology ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local/etiology ; Receptors, Chimeric Antigen/therapeutic use ; Receptors, G-Protein-Coupled/therapeutic use ; T-Lymphocytes
Chemical Substances	B-Cell Maturation Antigen ; GPRC5D protein, human ; Receptors, Chimeric Antigen ; Receptors, G-Protein-Coupled
Language	English
Publishing date	2022-06-21
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMoa2209900
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Shah, Urvi A / Maclachlan, Kylee H / Derkach, Andriy / Salcedo, Meghan / Barnett, Kelly / Caple, Julia / Blaslov, Jenna / Tran, Linh / Ciardiello, Amanda / Burge, Miranda / Shekarkhand, Tala / Adintori, Peter / Cross, Justin / Pianko, Matthew J / Hosszu, Kinga / McAvoy, Devin / Mailankody, Sham / Korde, Neha / Hultcrantz, Malin /

Hassoun, Hani / Tan, Carlyn R / Lu, Sydney X / Patel, Dhwani / Diamond, Benjamin / Shah, Gunjan / Scordo, Michael / Lahoud, Oscar / Chung, David J / Landau, Heather / Usmani, Saad Z / Giralt, Sergio / Taur, Ying / Landgren, C Ola / Block, Gladys / Block, Torin / Peled, Jonathan U / van den Brink, Marcel R M / Lesokhin, Alexander M

Clinical cancer research : an official journal of the American Association for Cancer Research

2022 Volume 28, Issue 23, Page(s) 5149–5155

Abstract: Purpose: Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty ... ...

Abstract	Purpose: Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the microbiome (abundance of butyrate-producing bacteria or stool butyrate concentration) and may be associated with multiple myeloma outcomes. Experimental design: We examined the relationship of dietary factors (via a food frequency questionnaire), stool metabolites (via gas chromatography-mass spectrometry), and the stool microbiome (via 16S sequencing - α-diversity and relative abundance of butyrate-producing bacteria) with sustained MRD negativity (via flow cytometry at two timepoints 1 year apart) in myeloma patients on lenalidomide maintenance. The Healthy Eating Index 2015 score and flavonoid nutrient values were calculated from the food frequency questionnaire. The Wilcoxon rank sum test was used to evaluate associations with two-sided P < 0.05 considered significant. Results: At 3 months, higher stool butyrate concentration (P = 0.037), butyrate producers (P = 0.025), and α-diversity (P = 0.0035) were associated with sustained MRD negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (P = 0.009) and sustained MRD negativity (P = 0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins P = 0.01, flavones P = 0.01, and flavanols P = 0.02). Conclusions: This is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production, and sustained MRD negativity in multiple myeloma, providing rationale to evaluate a prospective dietary intervention.
MeSH term(s)	Humans ; Multiple Myeloma/drug therapy ; Butyrates ; Neoplasm, Residual ; Diet, Healthy ; Diet, Vegetarian
Chemical Substances	Butyrates
Language	English
Publishing date	2022-09-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-22-0723
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Search results

Search options

Article ; Online: Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Nutrition perceptions, needs and practices among patients with plasma cell disorders.

More links

Kategorien

Order via subito

Article ; Online: CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

More links

Kategorien

Order via subito

Article ; Online: GPRC5D-Targeted CAR T Cells for Myeloma.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito